Emitefur

Known as: 3-((3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)carbonyl)benzoic acid, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester, 3-[3-(6-Benzoyloxy-3-cyrano-2-pyridyloxycarbonyl)benzoyl]-1-(ethoxymethyl)-5-fluorouracil, 3 (3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxymethyl-5-fluorouracil 
An orally available antimetabolite composed of the 1-ethoxymethyl derivative of 5-fluorouracil (5-FU) and the dihydropyrimidine dehydrogenase (DPYD… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
PURPOSE To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of… (More)
Is this relevant?
2000
2000
The antineoplastic effects of BOF-A2 (Emitefur), a 5-fluorouracil (5-FU) derivative, in capsule form were assessed in patients… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
1999
Review
1999
Patient preferences, quality of life issues, and economic considerations are driving the development of orally administered… (More)
Is this relevant?
Review
1999
Review
1999
During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine… (More)
  • figure 1
  • table I
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
1996
1996
BOF-A2 (emitefur: 3-(3-[6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl]benzoyl)-1-ethoxy- methyl-5- fluorouracil), a novel 5-FU (5… (More)
Is this relevant?
1996
1996
We investigated the combined effect of radiation and clinically relevant doses of emitefur (BOF-A2), a newly developed anti… (More)
  • table I
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
1994
1994
Oral BOF-A2 (Emitefur), a new derivative of 5-fluorouracil (5-FU) containing both 1-ethoxymethyl-5-FU (EMFU), a masked form of 5… (More)
Is this relevant?